Showing results (101-110 of 319) with videos related to
Sort By:
Pageof 32
Nucleic Acids Research|January 11, 2000
Human Immunodeficiency Virus Reverse Transcriptase and Protease Sequence Database: an expanded data model integrating natural language text and sequence analysis programsR Kantor, R Machekano, M J Gonzales, et al.Proceedings of the National Academy of Sciences of the United States of America|December 17, 2008
A transitional endogenous lentivirus from the genome of a basal primate and implications for lentivirus evolutionRobert J Gifford, Aris Katzourakis, Michael Tristem, et al.The Review of Scientific Instruments|November 2, 2010
Wide-field turbulence imaging with beam emission spectroscopyG R McKee, R J Fonck, M W Shafer, et al.Transfusion|July 1, 1979
Priapism during filtration leukapheresisM B Dahlke, S L Shah, W C Sherwood, et al.Journal of Virology|June 15, 2004
Sequencing-based detection of low-frequency human immunodeficiency virus type 1 drug-resistant mutants by an RNA/DNA heteroduplex generator-tracking assayAmit Kapoor, Morris Jones, R W Shafer, et al.Physical Review Letters|October 10, 2006
Detection of zero-mean-frequency zonal flows in the core of a high-temperature tokamak plasmaD K Gupta, R J Fonck, G R McKee, et al.AIDS Research and Therapy|February 8, 2023
Potential role of doravirine for the treatment of HIV-1-infected persons with transmitted drug resistanceSoo-Yon Rhee, Jonathan M Schapiro, Francesco Saladini, et al.The Journal of Infectious Diseases|March 1, 1993
A mutation in human immunodeficiency virus reverse transcriptase and decline in CD4 lymphocyte numbers in long-term zidovudine recipientsM J Kozal, R W Shafer, M A Winters, et al.Proceedings of the National Academy of Sciences of the United States of America|October 27, 2006
Genotypic predictors of human immunodeficiency virus type 1 drug resistanceSoo-Yon Rhee, Jonathan Taylor, Gauhar Wadhera, et al.Antimicrobial Agents and Chemotherapy|April 1, 1997
Human immunodeficiency virus type 1 reverse transcriptase genotype and drug susceptibility changes in infected individuals receiving dideoxyinosine monotherapy for 1 to 2 yearsM A Winters, R W Shafer, R A Jellinger, et al.Pageof 32